GlassScriptPhysician profile
Rizwan U Hassan
NPI 1174524003
$3,664.12
in general payments reported to CMS, 2019-2025
29 companies · $63.78 in 2025
The $63.78 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,984 · 2020: $1,186 · 2021: $72.69 · 2022: $174 · 2023: $100 · 2024: $83.89 · 2025: $63.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $247.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $782.53 | 2019-2020 | |
| Biogen, INC. | $499.37 | 2019-2025 | Tysabri, Vumerity |
| Amgen INC. | $361.58 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $348.65 | 2019-2020 | |
| Emd Serono, INC. | $206.10 | 2019-2020 | |
| Ucb, INC. | $167.50 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $140.26 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $123.38 | 2019 | |
| Lilly USA, LLC | $115.50 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $111.63 | 2022 | |
| Argenx US, INC. | $100.00 | 2023 | Vyvgart |
| Supernus Pharmaceuticals, INC. | $92.57 | 2019-2020 | |
| Genzyme Corporation | $78.66 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $63.43 | 2019-2020 | |
| Allergan, INC. | $61.83 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $61.83 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $51.94 | 2020 | |
| Travere Therapeutics, INC. | $46.76 | 2020 | |
| Genentech USA, INC. | $46.10 | 2020 | |
| Kyowa Kirin, INC. | $36.19 | 2020 | |
| Eisai INC. | $29.00 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $21.65 | 2020 | |
| Abbvie INC. | $21.00 | 2021 | |
| Amneal Pharmaceuticals LLC | $18.83 | 2020 | |
| Tanabe Pharma America, INC. | $17.91 | 2019 | |
| Lundbeck LLC | $17.66 | 2019 | |
| Acadia Pharmaceuticals INC | $15.32 | 2020 | |
| Medtronic, INC. | $14.58 | 2025 | Linq II |
| Livanova USA, INC. | $12.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rizwan Hassan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.